• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Ball is in Your Court: Agenda for Research to Advance the Science of Patient Preferences in the Regulatory Review of Medical Devices in the United States.

作者信息

Levitan Bennett, Hauber A Brett, Damiano Marina G, Jaffe Ross, Christopher Stephanie

机构信息

Janssen Research & Development, LLC, Titusville, NJ, USA.

RTI Health Solutions, Research Triangle Park, USA.

出版信息

Patient. 2017 Oct;10(5):531-536. doi: 10.1007/s40271-017-0272-6.

DOI:10.1007/s40271-017-0272-6
PMID:28831745
Abstract
摘要

相似文献

1
The Ball is in Your Court: Agenda for Research to Advance the Science of Patient Preferences in the Regulatory Review of Medical Devices in the United States.轮到你了：推进美国医疗器械监管审查中患者偏好科学的研究议程。
Patient. 2017 Oct;10(5):531-536. doi: 10.1007/s40271-017-0272-6.
2
Advancing regulatory science to bring novel medical devices for use in emergency care to market: the role of the Food and Drug Administration.推动监管科学发展，将用于急救护理的新型医疗设备推向市场：美国食品药品监督管理局的作用。
Ann Emerg Med. 2015 Apr;65(4):400-3. doi: 10.1016/j.annemergmed.2014.07.008. Epub 2014 Aug 13.
3
Institutional review boards and medical devices.机构审查委员会与医疗设备
JAMA. 1994 Sep 28;272(12):968-9.
4
FDA proposes "regulatory science" initiatives.美国食品药品监督管理局提出“监管科学”倡议。
Nurse Educ. 2011 Mar-Apr;36(2):75. doi: 10.1097/NNE.0b013e31820b5050.
5
Pharmaceuticals and medical devices: medical devices. Issue brief.药品和医疗器械：医疗器械。问题简报。
Issue Brief Health Policy Track Serv. 2012 Dec 31:1-35.
6
A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies.将患者对益处和风险的偏好纳入医疗技术监管评估的框架。
Value Health. 2016 Sep-Oct;19(6):746-750. doi: 10.1016/j.jval.2016.02.019.
7
FDA's new regulatory paradigms for in vitro diagnostic devices.美国食品药品监督管理局针对体外诊断设备的新监管模式。
Cytotherapy. 1999;1(4):353-7. doi: 10.1080/0032472031000141278.
8
Clinical investigations with medical devices. New rules.医疗器械的临床研究。新规则。
JAMA. 1981;245(20):2052-5.
9
Pharmaceuticals and medical devices: medical devices.药品和医疗器械：医疗器械。
Issue Brief Health Policy Track Serv. 2013 Dec 30:1-49.
10
Improving the security and privacy of implantable medical devices.提高可植入医疗设备的安全性和隐私性。
N Engl J Med. 2010 Apr 1;362(13):1164-6. doi: 10.1056/NEJMp1000745.

引用本文的文献

1
Research Priorities to Increase Confidence in and Acceptance of Health Preference Research: What Questions Should be Prioritized Now?优先研究事项以增强健康偏好研究的信心和接受度：现在应优先考虑哪些问题？
Patient. 2024 Mar;17(2):179-190. doi: 10.1007/s40271-023-00650-x. Epub 2023 Dec 16.
2
Discrete choice experiment versus swing-weighting: A head-to-head comparison of diabetic patient preferences for glucose-monitoring devices.离散选择实验与挥重权衡：血糖仪偏好的头对头比较——糖尿病患者视角
PLoS One. 2023 Jul 28;18(7):e0283926. doi: 10.1371/journal.pone.0283926. eCollection 2023.
3
Treatment preferences for preventive interventions for rheumatoid arthritis: protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project.

本文引用的文献

1
Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?运用离散选择实验为药品的获益-风险评估提供信息：我们准备好了吗？
Pharmacoeconomics. 2017 Sep;35(9):859-866. doi: 10.1007/s40273-017-0518-0.
2
Giving Patients' Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public-Private Project.让患者的偏好贯穿医疗治疗生命周期：PREFER公私合作项目。
Patient. 2017 Jun;10(3):263-266. doi: 10.1007/s40271-017-0222-3.
3
Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).
类风湿关节炎预防性干预措施的治疗偏好：创新药物倡议PREFER项目的混合方法案例研究方案
BMJ Open. 2021 Apr 8;11(4):e045851. doi: 10.1136/bmjopen-2020-045851.
4
Do preferences differ based on respondent experience of a health issue and its treatment? A case study using a public health intervention.偏好是否因受访者对健康问题及其治疗的体验而异？一项使用公共卫生干预措施的案例研究。
Eur J Health Econ. 2023 Apr;24(3):413-423. doi: 10.1007/s10198-022-01482-6. Epub 2022 Jun 18.
5
Advancing the Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation: A Summary Report of the Patient Preference Workshop.推动将患者偏好信息用作医疗产品评估中的科学证据：患者偏好研讨会总结报告
Patient. 2019 Dec;12(6):553-557. doi: 10.1007/s40271-019-00396-5.
6
Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs.早期药物研发过程中的患者偏好研究：协调利益相关者以确保研发计划满足患者需求。
Front Med (Lausanne). 2019 Apr 24;6:82. doi: 10.3389/fmed.2019.00082. eCollection 2019.
7
Symposium Title: Preference Evidence for Regulatory Decisions.研讨会主题：监管决策的偏好证据
Patient. 2018 Oct;11(5):467-473. doi: 10.1007/s40271-018-0311-y.
8
Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?将定量患者偏好数据纳入医疗保健决策过程：卫生技术评估是否落后了？
Patient. 2018 Jun;11(3):249-252. doi: 10.1007/s40271-018-0305-9.
9
Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis.从偏好的系统评价评估风险承受能力：以银屑病患者为例。
Patient. 2018 Jun;11(3):285-300. doi: 10.1007/s40271-017-0295-z.
10
Engagement of Canadian Patients with Rare Diseases and Their Families in the Lifecycle of Therapy: A Qualitative Study.参与加拿大罕见病患者及其家庭在治疗过程中的生命周期：一项定性研究。
Patient. 2018 Jun;11(3):353-359. doi: 10.1007/s40271-017-0293-1.
未接受治疗的 CD20+弥漫性大 B 细胞淋巴瘤或滤泡性淋巴瘤患者对利妥昔单抗皮下或静脉给药的偏好：来自一项前瞻性、随机、开放标签、交叉研究（PrefMab）的结果。
Ann Oncol. 2017 Apr 1;28(4):836-842. doi: 10.1093/annonc/mdw685.
4
Comparison of different approaches applied in Analytic Hierarchy Process - an example of information needs of patients with rare diseases.层次分析法中不同方法的比较——以罕见病患者的信息需求为例
BMC Med Inform Decis Mak. 2016 Sep 9;16(1):117. doi: 10.1186/s12911-016-0346-8.
5
Valuing Treatments for Parkinson Disease Incorporating Process Utility: Performance of Best-Worst Scaling, Time Trade-Off, and Visual Analogue Scales.结合过程效用评估帕金森病治疗方法：最佳最差标度法、时间权衡法和视觉模拟量表的表现
Value Health. 2016 Mar-Apr;19(2):226-32. doi: 10.1016/j.jval.2015.11.011. Epub 2016 Jan 21.
6
Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators.将患者偏好纳入药物研发和监管决策：一项针对癌症患者、护理人员和监管者的定量试点研究结果
Clin Pharmacol Ther. 2016 May;99(5):548-54. doi: 10.1002/cpt.332. Epub 2016 Feb 17.
7
Incorporating patient-preference evidence into regulatory decision making.将患者偏好证据纳入监管决策。
Surg Endosc. 2015 Oct;29(10):2984-93. doi: 10.1007/s00464-014-4044-2. Epub 2015 Jan 1.
8
Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis.照顾者对新兴杜氏肌营养不良症治疗方法的偏好：最佳-最差尺度法与联合分析的比较
Patient. 2015 Feb;8(1):19-27. doi: 10.1007/s40271-014-0104-x.
9
A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy.一种社区参与式方法，用于量化护理人员对杜氏肌营养不良症新兴疗法的益处和风险的偏好。
Clin Ther. 2014 May;36(5):624-37. doi: 10.1016/j.clinthera.2014.04.011.